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Perturbation of DNA replication initiation arrests human
cells in G1, pointing towards an origin activation check-
point. We used RNAi against Cdc7 kinase to inhibit repli-
cation initiation and dissect this checkpoint in ﬁbroblasts.
We show that the checkpoint response is dependent
on three axes coordinated through the transcription
factor FoxO3a. In arrested cells, FoxO3a activates the
ARF- |Hdm2- |p53-p21 pathway and mediates p15
INK4B
upregulation; p53 in turn activates expression of the
Wnt/b-catenin signalling antagonist Dkk3, leading to
Myc and cyclin D1 downregulation. The resulting loss of
CDK activity inactivates the Rb-E2F pathway and overrides
the G1-S transcriptional programme. Fibroblasts concomi-
tantly depleted of Cdc7/FoxO3a, Cdc7/p15, Cdc7/p53 or
Cdc7/Dkk3 can bypass the arrest and proceed into
an abortive S phase followed by apoptosis. The lack of
redundancy between the checkpoint axes and reliance on
several tumour suppressor proteins commonly inactivated
in human tumours provides a mechanistic basis for the
cancer-cell-speciﬁc killing observed with emerging Cdc7
inhibitors.
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Introduction
An estimated 30000 replication origins are spread along
human chromosomes and it is understood that chromatin
structure, adjacent sites of transcription and epigenetic para-
meters all affect origin selection (Mechali, 2001; Biamonti
et al, 2003). Initiation of DNA replication is a two-step
process. In early G1, the origin recognition complex (ORC)
cooperates with Cdc6 and Cdt1 in loading the Mcm2–7
helicase to form a ‘licensed’ pre-replicative complex
pre-RC). In late G1, the origin is ‘ﬁred’ by CDKs and Cdc7/
Dbf4 kinase. Cdc7 phosphorylates the Mcm2, 4 and 6
subunits, thereby inducing a conformational change that
stimulates MCM helicase activity and exposes a domain of
Mcm5 required for Cdk2-dependent loading of Cdc45 and the
replisome containing RPA, PCNA and DNA polymerase
a-primase (Sclafani and Holzen, 2007). In addition to its
highly conserved function in origin ﬁring, other, less well
understood, functions have been reported for Cdc7 kinase.
These include activation of the ATR-Chk1 pathway in
response to DNA damage and DNA replication stress
(Takeda et al, 1999; Costanzo et al, 2003; Dierov et al,
2004; Tenca et al, 2007; Kim et al, 2008), cohesin loading
onto chromatin required for chromosomal segregation in
mitosis (Takahashi et al, 2008), regulation of exit from
mitosis (Miller et al, 2009) and double-strand break forma-
tion during meiotic recombination (Matos et al, 2008).
As the two-step-replication model excludes the formation
of replication-competent origins once S phase has started, it
has been argued on the basis of experimental evidence that a
putative cell cycle checkpoint could delay progression from
G1 into S phase if replication initiation is perturbed (Blow
and Gillespie, 2008). In breast epithelial cells, for example,
RNAi against ORC2 impairs DNA replication, causing G1
arrest with low cyclin E–Cdk2 activity (Machida et al,
2005). Inhibition of pre-RC assembly by overexpressing a
stable form of geminin causes G1 arrest associated with low
CDK activity in ﬁbroblasts (Shreeram et al, 2002). Blocking
activation of the MCM helicase through RNAi against
CDC7 also causes G1 arrest in ﬁbroblasts and leads to
elevated p53 levels, p21 induction and hypo-phosphorylated
Rb (Montagnoli et al, 2004). These ﬁndings, therefore,
suggest that somatic cells can respond directly to impairment
of the DNA replication initiation machinery by blocking S
phase entry (Blow and Gillespie, 2008). In contrast, inhibition
of origin licensing or ﬁring has been shown to cause apopto-
tic cell death in a range of different cancer cell lines. This is
thought to arise as a result of transformed cells entering
S phase with inadequate numbers of competent origins to
complete chromosomal replication, arguing for loss of the
putative origin activation checkpoint in cancer. As only a
limited number of replication forks can be established when
replication initiation is perturbed, it is plausible that apopto-
sis is triggered as a result of fork stalling/collapse in cancer
cells with active intra S phase checkpoint mechanisms or
mitotic catastrophe arising from partially replicated chromo-
somes in more transformed cells (Blow and Gillespie, 2008).
The cancer-cell-speciﬁc killing reported for emerging
pharmacological Cdc7 inhibitors, while normal cells undergo
a non-genotoxic G1 arrest, has generated widespread
interest in small molecule inhibitors of the DNA replication
initiation machinery (Jackson, 2008; Montagnoli et al, 2008;
Swords et al, 2010). However, very little is known about the
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3381molecular architecture and circuitry of the proposed origin
activation checkpoint on which tumour speciﬁcity is depen-
dent. Here, we have used RNAi against CDC7 to inhibit
replication initiation and elucidate the molecular architecture
of the checkpoint in human ﬁbroblasts.
Results
Cdc7 depletion in IMR90 ﬁbroblasts causes cell cycle
arrest in G1
We set out to determine whether Cdc7 depletion can activate
a checkpoint response to impaired DNA replication initiation
by transfecting IMR90 cells with three different siRNAs with
sequences corresponding to the CDC7 cDNA. Notably, two
of the CDC7 siRNAs have been characterized in a previous
study (Montagnoli et al, 2004), whereas the third has
been validated by the manufacturer (Ambion, Warrington, UK)
(Supplementary Table 1 and Supplementary Figure 1A–D).
All three oligos efﬁciently reduced CDC7 mRNA levels
(Supplementary Figure 1B). On the basis of the highest
knock-down score and consistency in replicate experiments
(Supplementary Figure 1B–D), oligo CDC7-A (referred to here
as ‘CDC7-siRNA’) was used for all experiments shown, except
those in which siRNA speciﬁcity was shown with an alter-
native siRNA (oligo CDC7-B).
Relative to control-siRNA (CO), transfection of IMR90 cells
with CDC7-siRNA reduced CDC7 mRNA levels by 65% 48h
post-transfection, by 85% at 72h and by 495% at 96h
(Figure 1A). Correspondingly, in whole cell extracts (WCE),
Cdc7 protein levels started to fall by 24h and were undetect-
able from 48h until 120h post-transfection (Figure 1B).
Consistent with efﬁcient Cdc7 depletion, we noted a decrease
in total Mcm2 protein levels and a shift from hyper-
phosphorylated to slower migrating, hypo-phosphorylated
Mcm2 isoforms (Montagnoli et al, 2004) (Figure 1B).
Downregulation of Cdc7 expression caused a cessation of
cell proliferation with cell numbers reaching a plateau
48h post-transfection (Figure 1C). The majority of CDC7-
siRNA-transfected cells accumulated with G1 DNA content.
Although a small fraction of cells showed a G2/M DNA
content, cells with less than 2C DNA content were not
detected (Figure 1D), indicating that Cdc7-depleted cells
remained viable. In cells that were synchronized by release
from double thymidine block and directly transfected with
CDC7-siRNA, the majority of cells again showed a G1 DNA
content (90%), whereas the small G2/M peak noted for
asynchronous cells (9%) was lost with remaining cells
equally distributed between the S and G2/M fractions (5%
each) (Figure 1E). To provide further evidence that Cdc7
depletion is causing a G1 arrest, cells were transfected
with CDC7-siRNA and control-siRNA, pulsed with BrdU and
immunostained with anti-BrdU antibodies. In keeping with
the cell cycle proﬁle, the percentage of BrdU-incorporating
cells dropped from 22% in cells transfected with control-
siRNA (23% in untreated cells) to 2% in Cdc7-depleted cells
(Figure 1F). Interestingly, 6 days after transfection with
CDC7-siRNA, IMR90 cells re-expressed Cdc7 and resumed
cell proliferation, showing a degree of conﬂuency seen in
control cells (Supplementary Figure 1E–G).
To control for siRNA speciﬁcity, we studied an alter-
native CDC7-siRNA (oligo CDC7-B; Supplementary Table 1
and Supplementary Figure 1B and C) targeting a different
region of the transcript. Oligos CDC7-B and CDC7-A showed
comparable gene silencing efﬁcacy (mRNA and protein
reduction) and induced similar phenotypic effects (accumu-
lation of cells with G1 DNA content) (Figure 1; Supple-
mentary Figure 2A and B). Moreover, rescue experiments
were performed in which the RNAi effect was reversed
through expression of a CDC7 gene variant refractory to
silencing by oligo CDC7-A. Under these conditions, IMR90
cells were able to recover from the cell cycle arrest caused by
Cdc7 depletion, as shown by ﬂow cytometry and BrdU-
incorporation data strongly resembling those of control cells
(Supplementary Figure 3A–C). We, therefore, reasoned that
CDC7 oligos A and B are equivalent and that the cell cycle
arrest phenotype directly correlates with Cdc7 depletion and
is unlikely to be due to concomitant non-speciﬁc downregu-
lation of an unknown gene (off-target effects). Taken
together, these data show that after Cdc7 depletion diploid
human ﬁbroblasts arrest cell cycle progression in G1, remain-
ing in a non-proliferative state from which they can re-enter
the cell cycle after Cdc7 levels have been restored.
CDK activity and replication initiation factors are
downregulated in response to Cdc7 depletion
The Mcm2–7-replicative helicase is an important target for
S phase-promoting kinases during origin activation, and the
Mcm2 subunit, in particular, has been shown to be a sub-
strate for both CDK and Cdc7. Phosphosites have been
mapped in the N-terminal tail of Mcm2 for Cdc7 (Ser-40,
Ser-53 and Ser-108) and Cdk2 (Ser-13, Ser-27 and Ser-41)
in vitro and in vivo (Montagnoli et al, 2006). To test whether
the Cdc7-depletion-induced checkpoint response involves
downregulation of S phase-promoting CDK activity, we trans-
fected IMR90 cells with CDC7-siRNA and studied Mcm2
phosphorylation at the mapped CDK and Cdc7 phosphosites.
In keeping with a previous study (Montagnoli et al, 2004),
Cdc7 depletion caused a decrease in Mcm2 levels and
reduced the electrophoretic mobility of the protein in poly-
acrylamide gels, showing the presence of hypo-phospho-
rylated Mcm2 isoforms (Figure 2A). Although Mcm2 total
protein levels consistently dropped in Cdc7-depleted cells, the
extent of Mcm2 reduction varied between experiments. The
average reduction in the intensity of Mcm2 protein bands
(relative to control-siRNA-transfected cells) was 45% at
48h, 62% at 96h and 76% at 120h post-transfection (Image
J densitometry analysis). Mcm2 Ser-40/41 and Ser-53
phosphorylation was abolished when Cdc7 kinase was down-
regulated (48–120h post-transfection), whereas phospho-
rylation at the CDK phosphosites Ser-27 and Ser-41 was
signiﬁcantly reduced after 96h (Figure 2A). To conﬁrm
the loss of CDK activity in Cdc7-depleted cells, we carried
out in vitro kinase assays with immunoprecipitated Cdk2
(Figure 2B). As expected, in vitro phosphorylated, recombi-
nant truncated Rb protein was detected with an anti-Thr-821-
phosphorylated Rb antibody in IMR90 and MDA-MB231
breast cancer cells (controls), but not in IMR90 cells trans-
fected with CDC7-siRNA or treated with the CDK inhibitor
roscovitine.
The decline in Mcm2 levels in Cdc7-depleted cells
(Figure 2A) raises the possibility that perturbation of origin
activation may result in downregulation of replication initia-
tion factors and/or affect the stability on chromatin of
pre-RCs already formed. To address this question, IMR90
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chemically fractionated into WCE and chromatin-bound frac-
tions (CBF) and immunoblotted with antibodies against
replication initiation factors (Figure 2C). Orc4 levels in un-
treated and siRNA-transfected cells did not vary over the
course of the experiment. On the contrary, in Cdc7 depleted,
but not control cells, protein levels of Cdc6, Cdt1, Mcm2,
Dbf4, Mcm10 and Cdc45 were signiﬁcantly downregu-
lated, whereas levels of these replication initiation factors
associated with chromatin were also reduced. Notably, the
DNA polymerase processivity factor PCNA was undetectable
in CBF from Cdc7-depleted cells (Figure 2C).
Next, we sought to establish whether the Cdc7-depletion-
induced checkpoint response involves any known cell cycle
regulators of the G1-S transition. Compared with control
cells, at 96h post-transfection Cdc7-depleted cells showed a
marked increase in cyclin E levels, whereas cyclin A levels
were reduced below the detection limit (Figure 2D). The loss
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Figure 1 Cdc7 depletion in IMR90 ﬁbroblasts causes cell cycle arrest in G1. (A) Time course of CDC7 mRNA knock-down (KD) in IMR90 cells
relative to cells transfected with control-siRNA (CO). (B) Whole cell extracts (WCE) prepared from untreated (UT), CO and Cdc7
KD cells were
analysed by immunoblotting with the indicated antibodies (b-actin—loading control). (C) At the indicated time points, cell number was
measured in UT, CO and Cdc7
KD cell populations. (D) DNA content of UT, CO and Cdc7
KD cells at 96 and 120h post-transfection. (E) DNA
content of double thymidine-arrested cells (DTB), CO and Cdc7
KD cells 48h after release from double thymidine block and transfection, and
asynchronous Cdc7
KD cells 48h post-transfection. (F) At 96h post-transfection, cells were pulsed for 2h with BrdU, ﬁxed and detected with an
FITC-conjugated anti-BrdU antibody. DNA was stained with propidium iodide (PI). Numbers show the percentage of cells incorporating BrdU.
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(Figure 2C) further support the notion of a late G1 arrest in
Cdc7-depleted cells. The Cdc7-depleted cells also showed
early loss of Rb phosphorylation at Ser-807/811, thought to
be either Cdk4 or Cdk2 phosphorylation sites (Connell-
Crowley et al, 1997; Chi et al, 2008), slightly raised p16
levels, p53 stabilization and increased levels of p21
(Figure 2D). Phosphorylation of p53 at Ser-15 (Figure 2E)
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Figure 2 CDK activity and replication initiation factors are downregulated in response to Cdc7 depletion. (A) WCE prepared from IMR90 cells
transfected with control-siRNA (CO) and CDC7-siRNA (Cdc7
KD) were analysed by immunoblotting with the indicated antibodies (b-actin—
loading control). (B) WCE prepared from CO and Cdc7
KD cell populations and from CO cells treated with 200mM roscovitine (ROS) for 24h
(negative control) and MDA-MB231 breast cancer cells (positive control) were immunoprecipitated with anti-cyclin A and anti-cyclin E
antibodies. Cdk2 immunoprecipitates (Cdk2 IP) were subjected to an in vitro kinase assay using recombinant truncated Rb protein (p56) as
substrate. In vitro phosphorylation was detected with a speciﬁc anti-Rb-phospho-Thr-821 antibody. Note that lanes 1–8 were run on the same
polyacrylamide gel and proteins transferred to the same PVDF membrane by semi-dry electroblotting. The membrane was subsequently cut as
indicated for optimized immunodetection. (C) WCE and chromatin-bound protein fractions (CBF) prepared from untreated (UT), CO and
Cdc7
KD cells (96h post-transfection) were analysed by immunoblotting with the indicated antibodies (b-actin and histone H1—loading
controls). (D) WCE from UT, CO and Cdc7
KD cells (48 and 96h post-transfection) were analysed by western blotting with the indicated
antibodies (b-actin—loading control). (E) WCE from UT, CO and Cdc7
KD cells (48 and 96h post-transfection) and from cells treated for 24h
with 17mM cisplatin (Pt) were analysed by western blotting with the indicated antibodies (b-actin—loading control).
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detected in Cdc7-depleted or control cells, indicating that
the ATM/ATR checkpoint pathways were not activated.
These results show that Cdc7 depletion results in down-
regulation of replication initiation factors and low CDK
activity, consistent with the observed increase in p21 levels
and the appearance of hypo-phosphorylated Rb.
Cdc7 depletion affects expression of genes required
for cell cycle progression and proliferation
To investigate signalling pathways affected by CDC7 knock-
down, we performed gene expression microarray (GEM)
analysis on samples prepared from IMR90 cells transfected
with CDC7-siRNA and control-siRNA (84h post-transfection;
see Supplementary Materials and Methods). Differentially
regulated genes were analysed according to their membership
of Kyoto Encyclopedia of Genes and Genomes human signal-
ling pathways (Supplementary Table 2). The overall expres-
sion proﬁle of genes in the cell cycle cluster was signiﬁcantly
altered between control cells and Cdc7-depleted cells
(Po0.0001). Genes encoding Cdc6 and Mcm2–7, a number
of mitosis regulatory factors, A-, B- and D-type cyclins, and
Cdk1 and Cdk6 were all signiﬁcantly downregulated in Cdc7-
depleted cells, whereas CDKN2B (p15
INK4B) was strongly
upregulated (Supplementary Figure 5A). Genes in the p53
network cluster were also found to be differentially regulated
(Po0.0001; Supplementary Figure 5B). The DNA damage
checkpoint kinases ATM and ATR were strongly downregu-
lated in Cdc7-depleted cells (Supplementary Figure 5B), con-
sistent with the absence of p53 phosphorylation at Ser-15
(Figure 2E) and Chk1 phosphorylation at Ser-345 (Supple-
mentary Figure 4). Although the pro-apoptotic genes BAX
and FAS were upregulated, caspase 9 (CASP9) and caspase 3
(CASP3) were downregulated (Supplementary Figure 5B),
suggesting that Cdc7 depletion may sensitize ﬁbroblasts to
pro-apoptotic signals, but does not activate the cell death
effector machinery. Among p53-target genes, SIAH1, known
to ubiquitinate b-catenin (Matsuzawa and Reed, 2001), and
Dickkopf homolog 3 (DKK3), which blocks b-catenin accu-
mulation in the nucleus (Wei et al, 2006; Lee et al, 2009),
were strongly upregulated (Supplementary Figure 5B and C),
pointing towards possible coupling between the p53 network
and Wnt/b-catenin signalling pathway after CDC7 knock-
down. This supposition was further supported by the notion
that the overall expression proﬁle of genes in the Wnt-
signalling cluster was signiﬁcantly altered between control
and Cdc7-depleted cells (P¼0.014; Supplementary Table 2;
Supplementary Figure 5C). The GEM data indicate that the
Cdc7-depletion-induced checkpoint overrides the transcrip-
tional programme in a way that tilts the balance in favour of
cell cycle arrest and reduced competency for cell prolifera-
tion. The GEM data used here may be found in the Array
Express data repository (http://www.ebi.ac.uk/arrayexpress)
under accession number E-MEXP-2115.
The Cdc7-depletion-induced checkpoint is p53
dependent
As the ATM/ATR checkpoint pathway does not appear to be
active in Cdc7-depleted cells, we reasoned that the balance
between Hdm2 and p14
ARF may constitute the main mechan-
ism for controlling p53 levels. Immunoblot analysis of
nuclear extracts (NEs) prepared from Cdc7-depleted cells
conﬁrmed an increase in ARF levels, which correlated with
loss of Hdm2 and p53 stabilization (Supplementary Figure
6A). Hdm2 protein was also not detectable in nucleolar
subfractions prepared from Cdc7-depleted cells (data not
shown). In keeping with the biochemical data, Cdc7-depleted
cells showed strong ARF immunostaining compared with
control cells (Supplementary Figure 6B). Hdm2 transcript
levels increased two-fold in Cdc7-depleted cells relative to
control-transfected cells 72h post-transfection and were com-
parable at later time points, arguing against transcriptional
downregulation of Hdm2 because of siRNA off-target effects
(Supplementary Figure 7). A previous study in dermal ﬁbro-
blasts showed that the Cdc7-depletion-induced checkpoint is
dependent on p53 (Montagnoli et al, 2004). To conﬁrm an
active function for p53 in our experimental system, we used
RNAi to downregulate p53 in IMR90 cells previously arrested
by Cdc7 depletion (Supplementary Figure 8A). Notably,
whereas Mcm2 phosphorylation at Ser-27 was abolished in
Cdc7-depleted cells, phosphorylation at this mapped Cdk2
phosphosite was detectable in doubly depleted Cdc7/p53
cells. On the contrary, Mcm2 phosphorylation at the mapped
Cdc7 phosphosite was strongly reduced in both Cdc7- and
Cdc7/p53-depleted cells (Supplementary Figure 9). These
data show that S phase-promoting CDK activity was restored
in doubly depleted Cdc7/p53 cells. In keeping with the
ﬁndings reported by Montagnoli et al, doubly depleted
Cdc7/p53 cells failed to arrest cell cycle progression and
instead progressed through S/G2 (Supplementary Figure 6C
and D). Failure to elicit the Cdc7-depletion-induced check-
point under CDC7 and P53 double knock-down conditions,
however, eventually resulted in apoptotic cell death
(Supplementary Figure 6E and F). Interestingly, cytoplas-
matic protein fractions prepared from doubly depleted
Cdc7/p53 cells revealed reduced levels of the b-catenin
antagonist Dkk3 (Supplementary Figure 6G), supporting the
notion of possible coupling between the p53 network and
Wnt/b-catenin signalling pathway after Cdc7 depletion
(Supplementary Table 2 and Supplementary Figure 5B and C).
Note that in keeping with a previous report (Hsieh et al,
2004), peptide blocking and N-glycanase treatment identiﬁed
the different bands detected with Dkk3 antibody as N-glyco-
sylated Dkk3 isoforms (Supplementary Figure 10).
The Cdc7-depletion-induced checkpoint is dependent
on p53 activity upstream of Wnt/b-catenin signalling
antagonist Dkk3 to downregulate Myc and cyclin D1
expression
Dkk3 is known to block nuclear accumulation of b-catenin
(Lee et al, 2009), resulting in downregulation of its down-
stream targets including CCND1 (cyclin D1) and MYC
(Clevers, 2006). As DKK3 upregulation in Cdc7-depleted
cells is dependent on p53 (Supplementary Figures 5C and
6G), we reasoned that p53 may affect cell cycle progression
by indirectly blocking Wnt/b-catenin signalling. Indeed,
immunoblot analysis of cytoplasmatic fraction (CF) and
NE prepared from Cdc7-depleted cells showed reduced nucle-
ar b-catenin and low Myc and cyclin D1 levels in conjunction
with an increase in the inducible, faster migrating isoform of
Dkk3 (Figure 3A). Consistent with the biochemical data,
Cdc7-depleted cells showed only weak Myc and cyclin D1
immunostaining compared with control cells (Figure 3B).
Notably, inducible Dkk3 expression and reduced nuclear
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Figure 3 p53-dependent upregulation of Wnt/b-catenin signalling antagonist Dkk3 is required for Cdc7-depletion-induced cell cycle arrest.
(A) Cytoplasmatic protein fractions (CF) and crude nuclear extracts (NE) from untreated (UT), control-siRNA (CO) and CDC7-siRNA (Cdc7
KD)-
transfected IMR90 cells (72h post-transfection) were analysed by immunoblotting with the indicated antibodies (b-actin and Orc4—loading
controls). (B) At the same time point, CO and Cdc7
KD cells were ﬁxed and b-catenin, Myc and cyclin D1 detected by indirect
immunoﬂuorescence using a ﬂuorescein-labelled secondary antibody. (C, D) CF and NE samples prepared from CO, Cdc7
KD and doubly
depleted Cdc7/Dkk3 (Cdc7
KD/Dkk3
KD) cells 48 and 72h post-transfection were analysed by immunoblotting with the indicated antibodies.
(E) 72h post-transfection CO, Cdc7
KD and Cdc7
KD/Dkk3
KD cells were pulsed for 2h with BrdU, ﬁxed and detected with an FITC-conjugated
anti-BrdU antibody. Chromatin-bound PCNA and gH2A.X (inset: higher magniﬁcation) were detected by indirect immunoﬂuorescence with
anti-PCNA and anti-gH2A.X antibodies and a ﬂuorescein-labelled secondary antibody. DNAwas stained with propidium iodide (BrdU) or DAPI
(PCNA and gH2A.X). Apoptotic cell death was detected in doubly depleted Cdc7
KD/Dkk3
KD cells by (F) phase contrast microscopy and by
(G) immunoblot analysis of CF and NE with the indicated antibodies (b-actin and Orc4—loading controls).
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IMR90 cells arrested through speciﬁc activation of the p53
pathway by low dose actinomycin D (Choong et al, 2009)
(Supplementary Figure 11), further supporting a close rela-
tionship between p53-dependent Dkk3 upregulation and
DNA replication control.
To directly test whether the p53-Dkk3- |b-catenin axis is
essential for the checkpoint response, we downregulated
Dkk3 through RNAi in IMR90 cells previously arrested by
Cdc7 depletion (Supplementary Figure 8B). Immunoblot
analysis of CF and NE prepared at 48 and 72h post-transfec-
tion shows loss of the inducible form of Dkk3 in the Cdc7-
depleted background and conﬁrms maintenance of elevated
p53 and p21 levels (Figure 3C). Note that downregulation of
the slower migrating, heavily glycosylated Dkk3 isoforms
(upper bands) only occurs at later time points
(Supplementary Figure 10B and C). Cdc7 depletion alone
diminished the pool of nuclear b-catenin and reduced Myc
and cyclin D1 levels (Figure 3D). As expected, this resulted in
G1 arrest as shown by cells failing to incorporate BrdU
(Figure 3E), loss of chromatin-bound PCNA (Figure 3E) and
cyclin A and histone H3 Ser-10 phosphorylation becoming
undetectable (Figure 3D). Importantly, in doubly depleted
Cdc7/Dkk3 cells, nuclear levels of b-catenin, Myc and cyclin
D1 were restored 72h post-transfection (Figure 3D). In con-
trast to Cdc7-depleted cells, doubly depleted Cdc7/Dkk3 cells
did not arrest in G1 and instead progressed into S phase, as
shown by high levels of chromatin-bound PCNA (Figure 3E),
BrdU incorporation (Figure 3E), cyclin A detection
(Figure 3D) and ﬂow cytometry (Supplementary Figure
12C). Notably, doubly depleted Cdc7/Dkk3 cells exhibited
gH2A.X immunostaining indicative of double-strand breaks
(Figure 3E) and did not appear to progress to G2/M as shown
by the lack of histone H3 Ser-10 phosphorylation (Figure 3D).
Induction of apoptosis in doubly depleted Cdc7/Dkk3 cells
was conﬁrmed morphologically (Figure 3F), through detec-
tion of caspase 3 activation and PARP-1 cleavage (Figure 3G),
and by ﬂow cytometric detection of cells with less than 2C
DNA content (Supplementary Figure 12C). These results
show that Dkk3-mediated downregulation of Myc and cyclin
D1, critical components of the cell cycle engine required for
progression through G1 phase, is essential for a functioning
origin activation checkpoint.
The Forkhead transcription factor FoxO3a coordinates
the ARF- |Hdm2- |p53-p21, p53-Dkk3- |b-catenin and
p15
INK4B- |cyclin D–CDK axes of the origin activation
checkpoint
Cdc7-depleted IMR90 cells showed six-, seven- and four-fold
increases in CDKN2A (ARF), CDKN2B (p15) and CDKN1B
(p27) mRNA transcript levels (Supplementary Figure 13A).
As FoxO3a can mediate the expression of all three of these
cell cycle regulatory genes in response to different stimuli
(Brunet et al, 1999; Bouchard et al, 2007; Katayama et al,
2008), we hypothesized that this transcription factor could
represent an important node in the Cdc7-depletion-induced
origin activation checkpoint. Immunoblot analysis showed a
pool of FoxO3a present in the cytoplasm of untreated control
cells and revealed nuclear accumulation of FoxO3a in Cdc7-
depleted cells (Figure 4A). Concurrent with the nuclear
accumulation of FoxO3a in Cdc7-depleted cells, we noted
an increase in nuclear ARF, p53 and p21 levels and in nuclear
and cytoplasmatic p15 and p27 levels (Figure 4A). Protein
levels of these cell cycle regulators were not raised and Dkk3
expression was not induced in synchronized late G1 phase
control-transfected IMR90 cells or in the G1 DNA content
fraction collected by one-way sorting of propidium iodide
(PI)-stained control cells (Supplementary Figure 14). Hence,
the observed increase in checkpoint protein levels is not an
indirect consequence of cell cycle position. Co-knock-down
of CDC7 and FOXO3A (Supplementary Figure 8C) reduced
CDKN2A mRNA levels by 89%, CDKN2B levels by 85%
and CDKN1B levels by 50% compared with CDC7 knock-
down alone (Supplementary Figure 13B). Concordantly, ARF
became undetectable by western blotting and p53, p15, p21
and p27 were reduced to background levels seen in untreated
control cells (Figure 4A). When expression of these proteins
was compared in Cdc7-depleted and oxidatively stressed cells
(note that reactive oxygen species are known regulators of
FoxO family members), p53, p21, p15 and p27 upregulations
were found in both cell populations, whereas increased ARF
levels and inducible Dkk3 expression were restricted to Cdc7-
depleted cells (Supplementary Figure 15). This suggests that
inducible ARF and Dkk3 expression are more speciﬁc events
associated with DNA replication control, whereas p15 and
p27 upregulation in Cdc7-depleted-arrested cells overlaps
with a common FoxO-induced cell cycle arrest pathway.
Taken together, these expression proﬁles support the suppo-
sition that triggered by impaired origin activation FoxO3a
may, either directly through transcriptional mechanisms or
indirectly, mediate the expression of Dkk3, INK4 and CIP/KIP
CDK inhibitors.
We reasoned that if the origin activation checkpoint is
dependent on FoxO3a, doubly depleted Cdc7/FoxO3a cells
should bypass the cell cycle blockade and progress into
S phase. As predicted, ﬂow cytometric analysis of doubly
depleted Cdc7/FoxO3a cells 48h post-transfection revealed a
small S phase population, a marginally increased fraction of
cells with G2/M DNA content and a large population of cells
with less than 2C DNA content (Figure 4B). The notion that
doubly depleted Cdc7/FoxO3a cells had progressed into S
phase was further supported by positive immunostaining for
chromatin-bound PCNA and detection of BrdU incorporation
(Figure 4C). Notably, doubly depleted Cdc7/FoxO3a cells
incorporated only low levels of BrdU into DNA (Figure 4C,
insert) and showed strong immunostaining of the gH2A.X
surrogate marker for DNA fragmentation (Figure 4C).
Induction of apoptosis was conﬁrmed by ﬂow cytometry
(Figure 4B), morphologically (Figure 4D), and through detec-
tion of caspase 3 activation and PARP-1 cleavage (Figure 4E).
In Cdc7-depleted cells, p15 expression is strongly upregu-
lated at both transcriptional (Supplementary Figure 13A) and
protein level (Figure 5A and B). By binding to and inhibiting
cyclin D–CDK4/6 complexes, p15 may inactivate the CDK-Rb-
E2F pathway in Cdc7-depleted cells, which could be critical
for shifting the balance between growth-promoting and anti-
proliferative signals in favour of cell cycle arrest. To address
this question, we downregulated p15 in IMR90 cells pre-
viously arrested by Cdc7 depletion (Supplementary Figure
8D). Immunoblot analysis shows knock-down of p15 expres-
sion in the Cdc7-depleted background (Figure 5C). In contrast
to Cdc7-depleted cells arresting in G1, doubly depleted Cdc7/
p15 cells entered S phase despite elevated p53 and p21 levels
as shown by ﬂow cytometry (Supplementary Figure 12D),
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and increased cyclin Adetection (Figure 5C). Doubly depleted
Cdc7/p15 cells also exhibited replication stress in the form of
strong gH2A.X immunostaining (Figure 5D) and induced
apoptosis as conﬁrmed by ﬂow cytometry (Supplementary
Figure 12D), morphologically (Figure 5E), and through detec-
tion of caspase activation and PARP-1 cleavage (Figure 5F).
Importantly, single knock-down control experiments showed
that p15, FoxO3a, Dkk3 or p53 depletion alone does not cause
strong S phase stimulation or apoptosis in this experimental
system (Supplementary Figure 16).
Cdc7 depletion with an alternative CDC7-siRNA (oligo
CDC7-B) triggered the same molecular changes in the described
checkpoint pathways as CDC7 knock-down with oligo CDC7-A
(Supplementary Figure 2C). The cell cycle arrest pheno-
type was reversed through expression of a CDC7 gene variant
refractory to silencing by oligo CDC7-A (Supplementary Figure
3D and E). Moreover, the arrested phenotype was fully
reproducible in a different ﬁbroblast strain (Supplementary
Figure 17). These control experiments further reinforce our
ﬁndings and argue against RNAi off-target effects.
It can be postulated that if the checkpoint path-
ways elucidated here for Cdc7-depleted cells are manifested
by impaired origin activation, these pathways should be
similarly activated by depletion of other replication initiation
proteins. To address this question, we compared the cellular
response to Cdc7 depletion in IMR90 cells with the response
caused by RNAi against ORC2, an origin licensing factor
that acts upstream of Cdc7 in the DNA replication initiation
pathway. Indeed, ORC2 knock-down led to an accumulation
of cells with G1 DNA content (Supplementary Figure 18A and
B). As expected, immunoblotting revealed changes in protein
levels and subcellular localization of FoxO3a, ARF, p15, p21,
p27, p53 and Dkk3 similar to those found in Cdc7-depleted
cells (Supplementary Figure 18C). Moreover, CDK activity,
determined indirectly through Mcm2 phosphorylation at the
Cdk2 phosphosite Ser-27, was reduced and cyclin D1 down-
regulated in Orc2-depleted cells (Supplementary Figure 18C).
Thus, at least partially overlapping checkpoint pathways
appear to be activated by targeting either CDC7 or ORC2,
reinforcing the conclusion that the Cdc7-depletion-induced
checkpoint is triggered by impaired origin activation.
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Figure 4 FoxO3a-mediated upregulation of ARF and CDK inhibitors is an essential step for arresting cell cycle progression in Cdc7-depleted
cells. (A) Cytoplasmatic protein fractions (CF) and crude nuclear extracts (NE) prepared from CO, FoxO3a
KD, Cdc7
KD and doubly depleted
Cdc7/FoxO3a (Cdc7
KD/FoxO3a
KD) IMR90 cells 48h post-transfection were analysed by immunoblotting with the indicated antibodies
(b-actin and Orc4—loading controls). Note that the faster migrating band represents the hypo-phosphorylated, active form of p27 and the
slower migrating band its hyper-phosphorylated inactive form (Rodier et al, 2001; Chopra et al, 2002) (B) DNA content of Cdc7
KD and Cdc7
KD/
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KD cells 48h post-transfection. (C) 48h post-transfection CO, Cdc7
KD and Cdc7
KD/FoxO3a
KD cells were pulsed for 2h with BrdU, ﬁxed
and detected with an FITC-conjugated anti-BrdU antibody (inset: higher magniﬁcation). Chromatin-bound PCNA and gH2A.X were detected as
described in the legend to Figure 3. Apoptotic cell death was detected 48h post-transfection in doubly depleted Cdc7
KD/FoxO3a
KD cells (D)b y
phase contrast microscopy and (E) by immunoblot analysis of CF and NE with the indicated antibodies (b-actin and Orc4—loading controls).
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Cells have evolved elaborate checkpoint mechanisms for
maintenance of the genome. Checkpoints guard critical cell
cycle transitions by preventing future events from happening
if the prior event is not completed and error free. Previous
studies have shown that inhibition of replication initiation
proteins arrests the cell cycle in G1, pointing towards the
existence of a checkpoint that prevents premature entry into
S phase until a sufﬁcient number of origins are replication
competent (Blow and Gillespie, 2008). Here, we have
used RNAi against CDC7 to reveal the activities of the
origin activation checkpoint and to investigate its molecular
architecture.
Our results show that Cdc7 depletion arrests cell cycle
progression in diploid human ﬁbroblasts. Immunoblotting
showed that the DNA polymerase processivity factor PCNA
was not associated with chromatin in Cdc7-depleted cells,
whereas the proportion of BrdU-incorporating cells was
reduced by 490% compared with control cells. Moreover,
cyclin A, a marker for entry into S-G2-M phase, became
undetectable in arrested cells. Phosphorylation of Chk1
on Ser-345, involved in activation of this checkpoint
kinase in response to blocked DNA replication (Zhao and
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Figure 5 The Cdc7-depletion-induced cell cycle arrest is p15
INK4B dependent. (A) Upregulation of p15 levels in Cdc7-depleted IMR90 cells was
conﬁrmed by immunoblotting WCE prepared from CO cells and Cdc7-depleted cells 48, 96 and 120h post-transfection with antibodies against
p15 and b-actin (loading control). (B) Cdc7
KD and CO cells were ﬁxed 96h post-transfection and p15 detected by indirect immunoﬂuorescence
using a ﬂuorescein-labelled secondary antibody. (C) CFand NE prepared from CO, Cdc7
KD and doubly depleted Cdc7/p15 (Cdc7
KD/p15
KD) cells
72h post-transfection were analysed by immunoblotting with the indicated antibodies (b-actin and Orc4—loading controls). (D) 72h post-
transfection CO, Cdc7
KD and Cdc7
KD/p15
KD cells were pulsed for 2h with BrdU, ﬁxed and detected with an FITC-conjugated anti-BrdU
antibody. Chromatin-bound PCNA and gH2A.X were detected as described in Figure 3 legend. Apoptotic cell death was detected 72h post-
transfection in doubly depleted Cdc7
KD/p15
KD cells by (E) phase contrast microscopy and by (F) immunoblot analysis of CF and NE with the
indicated antibodies (b-actin and Orc4—loading controls).
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depleted cells, arguing against the cell cycle arrest being
triggered in early S phase by a signal generated from a
few stalled replication forks that escaped the block.
Downregulation of the DNA damage checkpoint controls
kinases ATM and ATR and the lack of p53 phosphorylation
on Ser-15 argues further against early S phase arrest in
Cdc7-depleted cells. These results, therefore, suggest that
ﬁbroblasts depleted of Cdc7 arrest before entry into S
phase. We found p53 and p21 levels to be elevated and Rb
hypo-phosphorylated in Cdc7-depleted cells, whereas in vitro
kinase assays conﬁrmed a loss of CDK activity, which could
mediate the G1 arrest.
Conceptually, the process of DNA checkpoint control is
viewed as analogous to a signal transduction pathway. In this
analogy, if replication initiation is impaired for any reason, a
signal is detected by ‘sensor’ proteins and then sent by
‘transducer’ proteins to ‘effector’ proteins, which block the
cell cycle until a sufﬁcient number of origins are replication
competent. Owing to experimental limitations of transient
RNAi gene silencing, in particular the half-life of the CDC7
message and/or protein, our study has been restricted to
elucidating the transducer and effector mechanisms of the
origin activation checkpoint. Future investigations into how
impaired replication initiation is sensed and signalled to
transducer proteins, will be critically dependent on the
availability of speciﬁc small molecule Cdc7 kinase inhibitors,
which should allow activation of the checkpoint on a more
rapid time scale.
As the FoxO subfamily has been previously implicated in
cell cycle arrest (Huang and Tindall, 2007), we reasoned
that this family of stress-activated transcription factors
might serve as transducer proteins in the origin activation
checkpoint. FoxO transcription factors have been shown to
rapidly modulate the expression of genes involved in cell
cycle transitions (Huang and Tindall, 2007) and themselves
are regulated by subcellular localization, with cytoplasmatic
sequestration preventing transactivation of target genes
(Calnan and Brunet, 2008). Our results show that Cdc7-
depletion causes nuclear accumulation of FoxO3a. Among
the cohort of known FoxO3a gene targets, we found CDKN2A
(ARF) (Bouchard et al, 2007), CDKN2B (p15) (Katayama et al,
2008) and CDKN1B (p27) (Chandramohan et al, 2008) to
be upregulated both at transcriptional and protein level in
Cdc7-depleted cells. We show that FoxO3a downregulation in
cells previously arrested by Cdc7 depletion reduces expres-
sion of these critical cell cycle regulators to background levels
and bypasses the G1 arrest with cells entering an abortive
S phase followed by apoptosis. The same phenotype was also
established by co-depletion of Cdc7 and p15, indicating that
p15 is an effector of the G1 arrest, most likely through
inhibiting cyclin D–CDK4/6 activity. Our results, therefore,
show that FoxO3a activity is essential for a functioning origin
activation checkpoint and highlight the importance of the
FoxO3a-p15 axis (Figure 6). Previous work has established
that degradation of the Xenopus homologue of p27 occurs at
replication origins and is coupled with the initiation of DNA
synthesis (Furstenthal et al, 2001; You et al, 2002), whereas in
human breast epithelial cells, p27 is stabilized after Orc2
depletion and associated with the cyclin E–Cdk2 complex
(Machida et al, 2005). Thus, it is possible that FoxO3a-
dependent p27 upregulation forms a separate axis of the
origin activation checkpoint that results in inhibition of the
cyclin E–Cdk2 complex.
We noted elevated levels of p53 and p21 in Cdc7-depleted
ﬁbroblasts. As the ATM/ATR checkpoint pathway (Abraham,
2001) does not appear to be active in these cells, FoxO3a-
dependent upregulation of ARF provides a plausible explana-
tion for p53 stabilization. By antagonizing the E3 ubiquitin
ligase activity of Hdm2, ARF is known to stabilize p53 and
increase its transcriptional activity (Pomerantz et al, 1998).
One way in which ARF activates nucleoplasmic p53 is by
sequestering Hdm2 in the nucleolus (Weber et al, 1999).
Given the absence of any detectable Hdm2 either in crude
NEs or nucleolar subfractions, however, we speculate that
in Cdc7-depleted cells, ARF stabilizes p53 through Hdm2
proteolysis (Zhang et al, 1998) rather than nucleolar seques-
tration (Figure 6). We show that p21 induction in Cdc7-
depleted cells is dependent on p53. The ability of p21 to
shut down the activity of E-type and A-type cyclin–CDK
complexes ensures that cell cycle progression is blocked in
G1. If the cell has managed to escape the checkpoint and
advance into S phase with an insufﬁcient number of replica-
tion-competent origins, p21 can block progression through S,
G2 and M phase by inhibiting A-type and B-type cyclin–CDK
complexes and by interfering with PCNA function, thereby
halting further advance of replication forks (Sherr and
Roberts, 1999). We show that p53 downregulation in ﬁbro-
blasts previously arrested in G1 by Cdc7 depletion bypasses
the cell cycle blockade and results in cells proceeding through
S phase to the G2/M boundary before inducing apoptosis.
We, therefore, conclude that the FoxO3a-ARF- |Hdm2-|p53-
p21 axis is also essential for a functioning origin activation
checkpoint (Figure 6).
GEMs revealed a second critical function for p53 in the
checkpoint. Among known p53-target genes that were differ-
entially expressed in cells arrested by CDC7 knock-down is
DKK3, a negative regulator of the Wnt/b-catenin signalling
pathway (Niehrs, 2006). Dkk3 is a glycoprotein that prevents
nuclear accumulation of b-catenin, resulting in downregula-
tion of its downstream targets MYC and CCND1 (Lee et al,
2009). As expected, immunoblotting showed an increase in
the inducible, faster migrating Dkk3 isoform in Cdc7-depleted
cells and revealed strongly diminished nuclear b-catenin
levels as well as Myc and cyclin D1 downregulation. Dkk3
upregulation was reversed in cells co-depleted of Cdc7 and
p21WAF1 CDK2
p53 Dkk3
Impaired origin 
activation
Myc
cyclin D1
Hdm2
p14ARF FoxO3a
p15INK4B CDK4/6
Figure 6 A proposed model of the origin activation checkpoint.
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were restored upon downregulation of Dkk3 in cells
previously arrested by Cdc7 depletion. We speculate that
Dkk3-mediated cyclin D1 downregulation halts progression
through most of G1, whereas a decrease in transcription of
the MYC gene prevents Myc-driven gene expression changes
that normally drive the cell through G1 (Figure 6). It can be
postulated, for example, that a sharp fall in Myc levels leads
to downregulation of the cyclin D2 and CDK4 genes and a
reduction in Cul1 levels, a protein required for p27 degrada-
tion (Eilers and Eisenman, 2008). Reduced Myc levels may
also attenuate the expression of E2F1-3 and prevent Myc-
Max-mediated repression of p15 and p21 expression (Eilers
and Eisenman, 2008). As Myc has been implicated in stabiliz-
ing pre-RCs assembled at origins (Dominguez-Sola et al,
2007), Dkk3-mediated downregulation of MYC expression
might also explain the decrease in chromatin-bound origin
licensing factors seen in Cdc7-depleted cells. The ability of
Myc to modulate the actions of a number of positive and
negative regulators of cell cycle advance provides a ﬁrm
rationale for the requirement to downregulate this critical
driver of cell proliferation if cells sense inhibition of the DNA
replication initiation pathway. Importantly, we show that
Dkk3 downregulation in Cdc7-depleted-arrested ﬁbroblasts
also bypasses the cell cycle blockade, enabling cells to
proceed into an abortive S phase followed by apoptosis.
These data highlight the critical function of Dkk3 in linking
the FoxO3a-ARF- |Hdm2- |p53 axis to the Wnt/b-catenin
signalling pathway (Figure 6). We conclude that FoxO3a
lies at the core of a complex molecular circuitry that resets
the regulatory dials of the cell cycle clock in response to
blocked-replication initiation and thereby shifts the balance
of growth-promoting and growth-inhibiting mechanisms in a
way that favours G1 arrest. Pathway speciﬁcity tests in
ﬁbroblasts arrested by oxidative stress (Chen et al, 2004) or
through speciﬁc activation of the p53 pathway by low dose
actinomycin D (Choong et al, 2009) show that while p15 and
p27 upregulation in Cdc7-depleted cells overlap with the
common FoxO-induced cell cycle arrest pathway (Huang
and Tindall, 2007), inducible ARF and Dkk3 expression are
more speciﬁc events associated with DNA replication control.
Our microarray data indicate that the resulting loss of CDK
activity inactivates the Rb-E2F signalling pathway, which in
turn overrides the regular E2F-driven G1/S transcriptional
programme.
The pathways elucidated in this study in response to
impaired origin activation comply with two essential criteria
of checkpoint control originally proposed by Hartwell and
Weinert (1989). First, checkpoints are considered external
control mechanisms that are not required for forward cell
cycle progression. Conforming to this deﬁning feature,
FoxO3a-mediated activation of the three checkpoint axes
does not occur during normal G1 progression when the
potential for errors in the DNA replication initiation pathway
is minimal. The second is the relief-of-dependence criterion,
which stipulates that ‘the existence of a control mechanism is
suggested when one ﬁnds chemicals, mutants or other con-
ditions that y permit a late event to occur even when an
early, normal prerequisite event is prevented’ (Hartwell and
Weinert, 1989). In line with this hallmark of checkpoint
control, double depletion of Cdc7 and any of the check-
point proteins FoxO3a, p15, p53 or Dkk3 abrogates the
checkpoint itself and allows S phase entry. Single knock-
downs of these checkpoint components, on the contrary, do
not cause strong S phase stimulation on their own.
Several different conditions must be met during G1 phase
to ensure origin activation and DNA synthesis. These include
origin recognition through ORC binding, origin licensing
through the assembly of ORC, Cdc6, Cdt1 and the replicative
MCM helicase into pre-RCs, origin activation through CDK
and Cdc7-dependent phosphorylation events resulting in
origin unwinding and the recruitment of the replisome
required for initiation of DNA synthesis. Thus, as noted by
Khodjakov and Rieder (2009), there is the possibility of
multiple checkpoints, each detecting one of these conditions
or, alternatively, that a range of abnormalities may cause a
single condition detected by just one checkpoint. A G1 arrest
phenotype, for example, has been reported in response to
RNAi against ORC2 (Machida et al, 2005) and inhibition of
MCM loading by overexpressing a stable form of geminin
(Shreeram et al, 2002) or MCM helicase activity by RNAi
against CDC7 (Montagnoli et al, 2004). Thus, the question
arises whether these abnormalities are activating multiple
different checkpoints or a single master checkpoint. It is of
interest in this context that in our study the cellular effects
of ORC2 knock-down were remarkably similar to those
caused by CDC7 knock-down, suggesting that overlapping
checkpoint pathways are governing at least origin licensing
and origin ﬁring. The activation of overlapping pathways by
Orc2 and Cdc7 downregulation also argues against the pos-
sibility that the checkpoint described here is triggered by loss
of other, less well understood, Cdc7 functions in, for example,
mitotic chromosomal segregation (Takahashi et al, 2008) or
DNA damage response (Takeda et al, 1999; Costanzo et al,
2003; Dierov et al, 2004; Tenca et al, 2007; Kim et al, 2008).
In separate studies, we found that RNAi against CDC7
in primary human breast and bronchial epithelial cells
triggers a cell cycle blockade that phenotypically and at the
molecular level strongly resembles the G1 arrest described
here for diploid human ﬁbroblasts (Rodriguez-Acebes et al,
2010; Kingsbury et al, in preparation). This suggests that
the origin activation checkpoint is conserved in somatic
cells of different embryological origin. The integrated nature
of the underlying molecular circuitry explains how cells
arrested by Cdc7 depletion can bypass the cell cycle arrest
if the activity of important constituents of any of the three
axes identiﬁed in this study is inhibited. Cells that bypass the
checkpoint are able to support a low level of DNA synthesis
and either arrest in S phase or proceed to the G2/M boundary
if p53 function is lost. One explanation for FoxO3a-, p15-,
p53- and Dkk3-depleted cells with reduced Cdc7 levels being
able to synthesize DNA is the initiation of replication forks
from isolated origins that escaped checkpoint function.
Irrespective of p53 status, entry into S phase with an insufﬁ-
cient number of replication-competent origins is lethal, with
cells experiencing replication stress and inducing apoptosis.
Recent studies have established that inhibition of the
DNA replication initiation machinery causes cancer-cell-
speciﬁc killing (Blow and Gillespie, 2008), validating replica-
tion initiation as a new target class for cancer cell chemotherapy
(Jackson, 2008). Inhibiting an early step in replication
initiation upstream of DNA polymerase should result in
G1 arrest and, therefore, be non-genotoxic in normal cells
with a functioning checkpoint. Given the reappearance of
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against CDC7, we speculate that the G1 arrest enforced in
normal cells might also be reversible. The high levels of
apoptosis reported for cancer cell lines subjected to inhibition
of origin licensing or ﬁring (Shreeram et al, 2002; Feng et al,
2003; Montagnoli et al, 2004) indicate that the origin activa-
tion checkpoint is most likely lost or impaired in transformed
cells. This is in keeping with the dependency of the under-
lying molecular circuitry on a number of tumour suppressor
proteins (p53, Hdm2, ARF, FoxO3a, Dkk3 and Rb), one or
more of which are commonly inactivated during tumourigen-
esis. Thus, our ﬁndings support the concept of emerging
pharmacological Cdc7 inhibitors (Montagnoli et al, 2008;
Swords et al, 2010) as potentially powerful anti-cancer agents
with broad tumour spectrum activity. Knowledge of the
complex regulatory network underlying the checkpoint may
help predict individual patient response to Cdc7 inhibitors in
the future.
Materials and methods
Cell culture and cell synchronization
IMR90 (ATCC# CCL-186), a diploid human ﬁbroblast adherent
cell strain derived from foetal lung tissue, was obtained from LGC
Standards (Middlesex, UK) at population doubling (PD) 12. All
culture passages and PDs were recorded and all experiments were
performed with IMR90 cells under a PD of 22. WI-38 (ATCC#
CCL-75) diploid human ﬁbroblasts were obtained from LGC
standards at PD 6. All experiments with WI-38 cells were performed
under a PD of 15. IMR90 and WI-38 cells were cultured at 371C with
5% CO2 in DMEM (Invitrogen, Paisley, UK) supplemented with 10%
deﬁned FCS (Invitrogen), 100U/ml penicillin and 100mg/ml
streptomycin. For preparation of synchronous cell populations,
IMR90 cells were synchronized in early S phase by two sequential
25h blocks in 2.5mM thymidine (Sigma, Gillingham, UK) separated
by a 12h interval without thymidine (Krude et al, 1997).
Cell treatments
IMR90 ﬁbroblasts were oxidatively stressed through H2O2 treatment
as described (Chen et al, 2004) with the following minor
modiﬁcations. Cells were cultured in medium containing 600mM
H2O2 for 2h. After 24h, cells were treated again for 2h with 600mM
H2O2 and collected 4h after the second treatment. Speciﬁc
activation of the p53 pathway in IMR90 cells was induced by 24h
low dose (1nM) actinomycin D treatment as described (Choong
et al, 2009).
Cell population growth assessment and cell cycle analysis
Phase contrast microscopy was performed with an inverted
Axiovert 200M (Carl Zeiss, Welwyn Garden City, UK) and
Axiovision software. Flow cytometric cell cycle analyses were
performed as described (Eward et al, 2004). The proportion of cells
with less than 2C DNA content was calculated as an estimate of the
apoptotic cell population.
Cell sorting
For preparation of G1 phase cell populations, 5 10
6 of each
asynchronous control cells and Cdc7-depleted cells were collected
and ﬁxed for 3h at  201C in 80% methanol in PBS with added
protease inhibitors (one complete EDTA-free protease inhibitor
cocktail tablet (Roche Diagnostics, Burgess Hill, UK) per 25ml of
buffer). Cells were precipitated by centrifugation at 500g for 5min
and resuspended in a mixture containing 50mg/ml PI, 20mg/ml
RNase A and protease inhibitors. The cells were sorted on a DAKO/
Beckman Coulter MoFlo High Speed Sorter (Beckman Coulter Inc.,
Orange County, CA). The forward scatter signal was used to trigger
the detection of cells and the PI signal ﬂuorescence was linearly
quantiﬁed to rationalize DNA content after excitation at 488nm in
the orange/red channel (613/20nm bandpass ﬁlter). Cells in G1
phase of the cell cycle were sorted through one-way sorting into
round-bottomed Falcon tubes containing PBS with protease
inhibitors (Roche Diagnostics). Cells were precipitated at 16000g
for 5min and lysed with modiﬁed RIPA buffer (300mM NaCl).
Cell fractionation and immunoprecipitation
For western blot analysis, cells were harvested and WCE and
subcellular fractions were prepared. For WCE, cells were lysed for
45min on ice in modiﬁed RIPA lysis buffer (50mM Tris–HCl,
300mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS,
1mM EDTA and protease inhibitors) and sonicated for 10s. For
crude nuclear extraction, cells were lysed in buffer containing
10mM HEPES pH 7.9, 10mM KCl, 1.5mM MgCl2, 0.34M sucrose,
10% glycerol, 0.1% Triton X-100, 1.0mM DTT and protease
inhibitors and gently homogenized. Nuclei were precipitated by
centrifuging at 1000g for 5min at 41C and the CF was removed. For
preparation of NE, nuclear pellets were washed twice with the same
buffer, lysed in modiﬁed RIPA buffer for 30min, sonicated and
centrifuged at 13000g. Nucleoli and CBF were isolated as described
(Muramatsu and Onishi, 1978; Kingsbury et al, 2005). In vitro
kinase assays were performed as described (Jinno et al, 2002) with
minor modiﬁcations. Brieﬂy, cell lysates were incubated at 41C for
2h with cyclin A and cyclin E antibodies. The kinase activity of
immunoprecipitated Cdk2 in complex with cyclin A and cyclin E
was assayed as described (Jinno et al, 1999). Phosphorylation of
truncated Rb (Cdk2 substrate; QED Bioscience, San Diego, CA) was
detected with anti-Rb phospho-Thr-821 antibody (Invitrogen).
Immunoblotting
Protein concentration was determined using the DC Bio-Rad protein
assay kit (Bio-Rad Hemel Hempstead, UK); 60mg of total protein
was loaded in each lane and separated by 4–20% SDS–PAGE.
Protein was transferred from polyacrylamide gels onto PVDF
membranes (Bio-Rad) by semi-dry electroblotting. Blocking, anti-
body incubations and washing steps were performed as described
(Kingsbury et al, 2005). Antibodies used for immunoblotting and
immunoﬂuorescence (see below) included caspase 3 from Novus
(Littleton, CO); Chk1-pSer-345 (2341) from Cell Signaling Technol-
ogy (Danvers, MA); caspase 9 (F-7), cyclin D1 (H-295), p16
INK4A
(H-156), c-Myc (N-262), PCNA (F-2), Cdc6 (180.2) and histone H1
(AE-4) from Santa Cruz (Santa Cruz, CA); FoxO3a, caspase 8,
b-catenin and phospho-histone H3 (Ser-10) from Millipore (Billerica,
MA); cyclin A (6E6) and cyclin E (Ab-4) (HE-172) from Thermo Fisher
Scientiﬁc (Fremont, CA); p27
KIP1, Orc4, Mcm2 (BM28), p21
WAF1,
cyclin B1, PARP-1, pRb and Orc2 from BD Biosciences (Oxford, UK);
p15
INK4B (15PO6), Cdt1, Hdm2 and Dkk3 from Abcam (Cambridge,
UK); p53 (Ab-6) from Merck (Beeston, UK); Cdc7 from MBL
International (Woburn, MA); p14
ARF (DCS-240) and b-actin from
Sigma; p53 phospho-Ser-15, Rb phospho-Ser-807/811, phospho-
histone gH2A.X (Ser-139) from New England Biolabs (Hitchin, UK)
and Mcm2 phospho-Ser-53, Mcm2 phospho-Ser-27, Mcm2 phospho-
Ser-41, Mcm2 phospho-Ser-40/41 and Mcm2 phospho-Ser-108 from
Bethyl Laboratories (Montgomery, TX). Afﬁnity-puriﬁed rabbit
polyclonal anti-geminin antibody G95 was generated as described
(Wharton et al, 2004). Afﬁnity-puriﬁed rabbit polyclonal antibodies to
Mcm10, Cdc45 and Dbf4 were generated by Eurogentec (Seraing,
Belgium) following the manufacturer’s protocol. The positive control
lysate for p53 phospho-Ser-15 was prepared from IMR90 cells treated
with 17mM cisplatin for 24h (Pabla et al, 2008). Neuroblastoma SK-N-
SH cell lysate from Insight Biotechnologies (Wembley, UK) was used
as a positive control for Dkk3 protein. Immunodetection of Dkk3 was
blocked by preincubation of Dkk3 antibody with recombinant human
Dkk3 (1118-DK-050; R&D Systems Europe, Abingdon, UK) (1:1 w/w).
N-glycanase digestion
Cytoplasmatic protein fractions (125mgo r5 0mg total protein) were
treated with N-glycanase (recombinant from Chriseobacterium
(Flavobacterium) meningosepticum, expressed in Escherichia coli;
ProZyme, Hayward, CA) as described (Krupnik et al, 1999).
Immunoﬂuorescence
For detection of BrdU incorporation, cells pulsed for 2h with 100mM
BrdU were ﬁxed with 3.7% paraformaldehyde for 5min and
permeabilized with 0.2% Triton X-100 for 5min. Coverslips were
incubated with 2N HCl for 1h, washed with PBS and incubated for
1h at 371C with primary anti-BrdU antibody (Alexis Biochemicals,
Exeter, UK), diluted 1/10 vol/vol in 0.1% BSA in PBS containing
50ng/ml PI and 50ng/ml RNase A. Fluorescence confocal micro-
scopy of random ﬁelds of cells was performed on a Leica TCS SP
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rhodamine (red) and ﬂuorescein (green) channels were obtained
using Leica TCS PowerScan software. At least 400 cells were
routinely scored for each treatment and quantitated as percentages
of the total number of cells. Indirect immunoﬂuorescence of
chromatin-bound PCNA was performed as described (Miura and
Sasaki, 1999) with minor modiﬁcations. For detection of b-catenin,
Myc, cyclin D1, p15
INK4B and g-H2A.X, after paraformaldehyde
ﬁxation and permeabilization, coverslips were saturated with
blocking buffer (5% BSA in PBS) for 1h at RT, incubated with
primary antibody diluted in blocking buffer for 1h at 371C and
incubated overnight at 41C. FITC-conjugated anti-mouse antibody
from Dako (Glostrup, Denmark) was used at dilution 1/1000.
Slides were mounted in Vectashield mounting medium (Vector
Laboratories, Peterborough, UK) with 1.5mg/ml DAPI to visualize
DNA. Coverslips for p14
ARF detection were ﬁxed with methanol/
acetone (3:2 vol/vol) and stained as described above.
RNA interference
CDC7, p53 and CDKN2B (p15
INK4B) expression was inhibited
with double-stranded RNA oligos for CDC7 (A- and B- custom,
and V—validated siRNAs), p53 (custom siRNA) and p15INK4B
(silencer pre-designed and validated siRNAs) synthesized by
Ambion (Supplementary Table 1). DKK3 was speciﬁcally inhibited
with a cocktail of two ON-TARGET plus siRNAs (J-018352-11
and -12; Dharmacon, Fremont, CA) and FOXO3A was inhibited
with siGENOME SMART pool (M-003007-02-0005, Dharmacon).
Non-targeting siRNA was used as a negative control. Lipofectamine
2000 (Invitrogen) was used in all transfections according to the
manufacturer’s recommendations. Brieﬂy, cells were seeded at a
density to reach 50% conﬂuence on the day of transfection. The
transient transfections were performed using 10nM of CDC7 siRNA
duplex or 10nM of ORC2 siRNA duplex. For double knock-downs,
cells were ﬁrst transfected with CDC7-siRNA and after 72h (after
replating at low density for CO cells) transfected with either CDC7
(10nM) and control (10nM) oligos, or CDC7 (10nM) and p53
(10nM) or FOXO3A (10nM) oligos. DKK3 and p15INK4B cotrans-
fections were performed with CDC7 oligo (10nM) and a cocktail
of two DKK3 oligos (each 10nM) or a cocktail of p15INK4B oligos 1,
2 and 3 (each 5nM). In this case, CDC7 oligo pulsing at 72h was
adjusted with 20 and 15nM control (CO) oligo, respectively, to
reach the same amount of oligos in both samples (single and double
knock-down). For p53, Dkk3, FoxO3a and p15 single knock-downs,
cells were ﬁrst transfected with CO oligo and after 72h replated at
low density and transfected with CO, CO and p53-siRNAs (p53
KD),
or CO and DKK3 (Dkk3
KD) or FOXO3A (FoxO3a
KD) or CDKN2B
(p15
KD) oligos. siRNAs were complexed with transfection reagent in
serum-free and antibiotic-free culture medium according to the
manufacturer’s instructions (Invitrogen). Cells were incubated from
48 to 120h. All experiments were performed at least three times.
The transfection efﬁciency was determined for ﬂuorescein-
conjugated non-speciﬁc siRNA-transfected cells (BLOCK-iT Trans-
fection Optimization kit; Invitrogen) using a Leica TCS SP confocal
ﬂuorescence microscope. Selective silencing of the corresponding
proteins was conﬁrmed by western blotting. For rescue experi-
ments, the full 1725bp CDC7 cDNA sequence containing four silent,
single base pair mutations in the 21bp CDC7-siRNA (oligo-A)
interaction region was inserted into pCMV6-AC expression vector
(OriGene) to fully abolish the siRNA effect.
RNA extraction and qRT–PCR
To evaluate the efﬁciency of transfection with CDC7, p53, DKK3,
p15INK4B and FOXO3A siRNAs, mRNA transcription levels of
CDC7, p53, p15INK4B, DKK3 isoforms A and B and FOXO3A were
detected by qRT–PCR. Total RNA was isolated using a PureLink
Micro-to-Midi kit (Invitrogen) according to the manufacturer’s
instructions. Reverse transcription reactions using 40ng of total
RNA in a ﬁnal reaction volume of 20ml were performed in one step
using SuperScript III Platinum SYBR Green One Step qRT–PCR Kit
(Invitrogen). Relative quantitation data were obtained using
the comparative Ct method with Realplex software according to
the manufacturer’s protocol (Eppendorf, Heidelberg, Germany).
Glyceraldehyde-3-phosphate dehydrogenase was used to normalize
each of the extracts for ampliﬁable human DNA. Primers
(Supplementary Table 3) were provided by Euroﬁns MWG Operon
(Ebersberg, Germany). Cycle conditions are available upon request.
Additional information on cRNA labelling and hybridization for
microarray and Microarray data processing and analysis is available
in the Supplementary data section.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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